Host-targeted Approaches
for Prevention and treatment
of Hospital-Acquired
Pneumonia

News & events

News & Events

This leaflet contains a concise overview of the project’s concept and objectives; the presentation of two clinical trials conducted within the project; and highlights the various outputs we will offer to patients and the scientific and medical communities. See the leaflet

HAP2 kick-off meeting

13/01/20 - 14/01/20

All partners attended the 2-day meeting, filled with enthusiasm and collaboration as we planned the first year of the project. Over 2020, we’ll be focused on planning for our two clinical trials: PREV-HAP and TREAT-HAP, which will start in the next year in France, Spain and Greece. We’ll also...

HAP² project

“HAP2” is a 5-year project involving 10 partners from 6 countries, which aims to develop host-directed drugs and biomarkers to enhance the prevention and treatment of hospital-acquired pneumonia (HAP): an infectious disease of major concern for Europe, and develop precision medicine in infectious diseases.

HAP?

HAP is defined as a respiratory tract infection that occurs 48 hours or more after hospital admission. It is the most frequent cause of hospital-acquired infections and the main cause of antibiotics consumption in European hospitals.

5 years

2020 > 2024

600

Patients

10

Partners

6

Countries

Funding :

9 996 350€

Partners